PATH has developed this comprehensive suite of scientific communications materials to support evidence-based introduction and scale-up of DMPA-SC and self-injection (SI).

This resource provides a high-level summary of the current state of self-injection policy development, implementation, and monitoring in each of the Injectables Access Collaborative’s 11 focus countries: Benin, DRC, Ghana, Kenya, Madagascar, Malawi, Mozambique, Nigeria, Togo, Uganda, and Zambia. The policy cycle landscape (i.e., policy development, implementation, and monitoring) features an overview of the enabling environment for self-injection in each country, including general self-injection and self-care policies, as well as local authorizations for task-sharing/task-shifting. The information is current as of Quarter 2, 2025.

This webinar held on January 16, 2025 was hosted by the Injectables Access Collaborative Learning and Action Network in collaboration with the Reproductive Health Supplies Coalition’s (RHSC) New and Underused Reproductive Health Technologies Caucus (NURHT).  The discussion focused on advocacy strategies for reproductive health product introduction, scale-up, and institutionalization, emphasizing what it takes to see tangible change.

Presenters shared advocacy strategies and tactics that have successfully driven change—highlighting what is needed in the often-complex space between securing an advocacy win and seeing progress toward the desired outcome. Topics included increasing access to DMPA-SC self-injection, advancing menstrual health product standards, and facilitating country-level procurement of the hormonal intrauterine device (IUD).

Through the Self-injection Ambassadors initiative, the Injectables Access Collaborative (AC) brings together experienced, influential individuals who can elevate the evidence-based potential of self-injection in their daily work and through new opportunities facilitated by the AC. In addition to acting as resources for countries undertaking the self-injection journey, Ambassadors serve as global advocates on self-injection best practices—engaging donors, normative agencies, and implementing partners as appropriate. More broadly, Ambassadors also champion self-care for sexual and reproductive health. For more information, contact FPoptions@path.org.

Tools for advocacy and communications to increase contraceptive access and options

DMPA-SC is transforming contraceptive access, use, and choice for women and adolescent girls. Advocates play an important role in making sure their country’s policies and funding support access to a broad method mix, including options like DMPA-SC and self-injection.

The Injectable Access Collaborative’s DMPA-SC Advocacy Pack is designed to accelerate your advocacy efforts. It consists of evidence-based materials for advocates to use both for their own strategy development and for direct advocacy with decision-makers. Available in English and French in PDF, Word, and PowerPoint formats, materials are customizable and unbranded so that you can tailor them to your country context. Advocacy Pack for Subcutaneous DMPA. Product brand name Sayana Press.

This DMPA-SC Advocacy Pack brief offers an overview of key policies that affect introduction and scale-up of injectable contraceptives, including DMPA-SC.

This DMPA-SC Advocacy Pack brief offers concise, evidence-based information to help answer common questions and dispel myths about injectable contraception.

This DMPA-SC Advocacy Pack brief summarizes recent evidence from African countries on the costs and cost-effectiveness of DMPA-SC. Key findings include that DMPA-SC may help reduce service delivery costs by catalyzing expansion of channels closest to women and that self-injected DMPA-SC is cost-saving as compared to clinic-administered DMPA-IM when accounting for costs to women and health systems.

Using simple messages, this DMPA-SC Advocacy Pack case statement describes reasons why DMPA-SC is a valuable and game-changing addition to a broad contraceptive method mix.

These DMPA-SC Advocacy Pack briefs outline existing evidence on DMPA-SC grouped into top-line messages featuring data from different countries. Several “spotlight” handouts on specific topics can be paired with the summary brief as needed. All handouts can be printed and distributed directly to decision-makers.